The immune response: Targets for the treatment of severe sepsis

International Journal of Inflammation

Volumn 2012, Issue , 2012, Pages

  Bernard, Aline M ^a,b   Bernard, Gordon R ^c  

^a Nutrition Obesity Research Center at the University of Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFELIMOMAB; ANTITHROMBIN III; AUTACOID; BACTERIUM LIPOPOLYSACCHARIDE; CORTICOSTEROID; CYTOFAB; DROTRECOGIN; FLUDROCORTISONE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 6; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; MONOCLONAL ANTIBODY HA1A; PLACEBO; RECOMBINANT THROMBOMODULIN; RESATORVID; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CYTOKINE PRODUCTION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE BACTERIUM; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; INHIBITION KINETICS; LOW DRUG DOSE; MEDICAL RESEARCH; META ANALYSIS (TOPIC); MORTALITY; MYOPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY INFECTION; SEPSIS; SEPTIC SHOCK;

EID: 84876511903     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2012/697592     Document Type: Review

References (57)

1. Rice T. W., Bernard G. R., Therapeutic intervention and targets for sepsis. Annual Review of Medicine 2005 56 225 248 2-s2.0-14544299688 10.1146/annurev.med.56.082103.104356 (Pubitemid 40299782)
2. Hotchkiss R. S., Karl I. E., The pathophysiology and treatment of sepsis. New England Journal of Medicine 2003 348 2 138 150 2-s2.0-0037426726 10.1056/NEJMra021333 (Pubitemid 36056721)
3. Skrupky L. P., Kerby P. W., Hotchkiss R. S., Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology 2011 115 6 1349 1362
4. Dellinger R. P., Levy M. M., Carlet J. M., Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 2008 36 1 296 327
5. Kotsaki A., Giamarellos-Bourboulis E. J., Emerging drugs for the treatment of sepsis. Expert Opinion on Emerging Drugs 2012 17 3 379 391 10.1517/14728214.2012.697151
6. Fink M. P., Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide. Critical Care Medicine 1993 21 supplement 2 S32 S39 2-s2.0-0027405583 (Pubitemid 23057711)
7. Ziegler E. J., Fisher C. J., Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. H., Allen I. E., Berger H. J., Knatterud G. L., LoBuglio A. F., Smith C. R., Kett D. H., Elser B., Chan J. C., Kelly G., Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. New England Journal of Medicine 1991 324 7 429 436 2-s2.0-0026016470
8. Greenman R. L., Schein R. M. H., Martin M. A., Wenzel R. P., MacIntyre N. R., Emmanuel G., Chmel H., Kohler R. B., McCarthy M., Plouffe J., Russell J. A., A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. Journal of the American Medical Association 1991 266 8 1097 1102 2-s2.0-0025917510 10.1001/jama.266.8. 1097
9. Bone R. C., Balk R. A., Fein A. M., Perl T. M., Wenzel R. P., Reines H. D., Quenzer R. W., Iberti T. J., Macintyre N., Schein R. M. H., Trenholme G., Niederman M., Chalfin D., Jebson P., Abalos A., Oropello J., Empson P., Caminitii S., Greenman R., A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Critical Care Medicine 1995 23 6 994 1006 2-s2.0-0029043636 10.1097/00003246-199506000-00003
10. Alejandria M. M., Lansang M. A., Dans L. F., Mantaring J. B., Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database of Systematic Reviews 2002 1 CD001090 2-s2.0-19244368415
11. Angus D. C., Birmingham M. C., Balk R. A., Scannon P. J., Collins D., Kruse J. A., Graham D. R., Dedhia H. V., Homann S., Macintyre N., E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. Journal of the American Medical Association 2000 283 13 1723 1730 2-s2.0-0034607323 (Pubitemid 30196213)
12. McCloskey R. V., Straube R. C., Sanders C., Smith S. M., Smith C. R., Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1994 121 1 1 5 2-s2.0-0028557981
13. Salomao R., Martins P. S., Brunialti M. K., TLR signaling pathway in patients with sepsis. Shock 2008 30 supplement 1 73 77 10.1097/SHK. 0b013e318181af2a
14. Rice T. W., Wheeler A. P., Bernard G. R., Vincent J. L., Angus D. C., Aikawa N., Demeyer I., Sainati S., Amlot N., Cao C., Ii M., Matsuda H., Mouri K., Cohen J., A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Critical Care Medicine 2010 38 8 1685 1694 2-s2.0-77954953617 10.1097/CCM.0b013e3181e7c5c9
15. Annane D., Bellissant E., Bollaert P. E., Briegel J., Confalonieri M., De Gaudio R., Keh D., Kupfer Y., Oppert M., Meduri G. U., Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. Journal of the American Medical Association 2009 301 22 2362 2375 2-s2.0-67049108021 10.1001/jama.2009.815
16. Batzofin B. M., Sprung C. L., Weiss Y. G., The use of steroids in the treatment of severe sepsis and septic shock. Best Practice & Research 2011 25 5 735 743
17. Cronin L., Cook D. J., Carlet J., Heyland D. K., King D., Lansang M. A. D., Fisher C. J., Corticosteroid treatment for sepsis: a critical appraisal and meta- analysis of the literature. Critical Care Medicine 1995 23 8 1430 1439 2-s2.0-0029090390 10.1097/00003246-199508000-00019
18. Annane D., Sebille V., Charpentier C., Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Journal of the American Medical Association 2002 288 7 862 871 10.1001/jama.288.7.862
19. Sprung C. L., Annane D., Keh D., Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine 2008 358 2 111 124 10.1056/NEJMoa071366
20. Markovitz B. P., Goodman D. M., Watson R. S., Bertoch D., Zimmerman J., A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: what is the role of steroids? Pediatric Critical Care Medicine 2005 6 3 270 274 2-s2.0-19444369637 10.1097/01.PCC.0000160596.31238.72 (Pubitemid 40724275)
21. Qiu P., Cui X., Barochia A., Li Y., Natanson C., Eichacker P. Q., The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opinion on Investigational Drugs 2011 20 11 1555 1564 10.1517/13543784.2011.623125
22. Reinhart K., Karzai W., Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Critical Care Medicine 2001 29 supplement 7 S121 S125 2-s2.0-0034913364 (Pubitemid 32681594)
23. Abraham E., Wunderink R., Silverman H., Perl T. M., Nasraway S., Levy H., Bone R., Wenzel R. P., Balk R., Allred R., Pennington J. E., Wherry J. C., Efficacy and safety of monoclonal antibody to human tumor necrosis factor in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. Journal of the American Medical Association 1995 273 12 934 941 2-s2.0-0028957549 10.1001/jama.273.12.934
24. Cohen J., Carlet J., INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor in patients with sepsis. Critical Care Medicine 1996 24 9 1431 1440 2-s2.0-0029835023 (Pubitemid 26313741)
25. Abraham E., Anzueto A., Gutierrez G., Tessler S., San Pedro G., Wunderink R., Dal Nogare A., Nasraway S., Berman S., Cooney R., Levy H., Baughman R., Rumbak M., Light R. B., Poole L., Allred R., Constant J., Pennington J., Porter S., Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. The Lancet 1998 351 9107 929 933 2-s2.0-0032495658 10.1016/S0140-6736(00)80009-4 (Pubitemid 28138465)
26. Reinhart K., Wiegand-Löhnert C., Grimminger F., Kaul M., Withington S., Treacher D., Eckart J., Willatts S., Bouza C., Krausch D., Stockenhuber F., Eiselstein J., Daum L., Kempeni J., Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195 F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Critical Care Medicine 1996 24 5 733 742 2-s2.0-9344246862
27. Reinhart K., Menges T., Gardlund B., Zwaveling J., Smithes M., Vincent J. L., Tellado J. M., Salgado-Remigio A., Zimlichman R., Withington S., Tschaikowsky K., Brase R., Damas P., Kupper H., Kempeni J., Eiselstein J., Kaul M., Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Critical Care Medicine 2001 29 4 765 769 2-s2.0-0035046049 (Pubitemid 32299714)
28. Panacek E. A., Marshall J. C., Albertson T. E., Johnson D. H., Johnson S., MacArthur R. D., Miller M., Barchuk W. T., Fischkoff S., Kaul M., Teoh L., Van Meter L., Daum L., Lemeshow S., Hicklin G., Doig C., Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 2004 32 11 2173 2182 2-s2.0-8544262221 10.1097/01.CCM.0000145229.59014.6C (Pubitemid 39491795)
29. Rice T. W., Wheeler A. P., Morris P. E., Paz H. L., Russell J. A., Edens T. R., Bernard G. R., Safety and efficacy of affinity-purified, anti-tumor necrosis factor ovine fab for injection (CytoFab) in severe sepsis. Critical Care Medicine 2006 34 9 2271 2281 2-s2.0-33747502519 10.1097/01.CCM.0000230385. 82679.34 (Pubitemid 44260009)
30. Fisher C. J. Jr, Dhainaut J. F. A., Opal S. M., Pribble J. P., Balk R. A., Slotman G. J., Iberti T. J., Rackow E. C., Shapiro M. J., Greenman R. L., Reines H. D., Shelly M. P., Thompson B. W., LaBrecque J. F., Catalano M. A., Knaus W. A., Sadoff J. C., Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. Journal of the American Medical Association 1994 271 23 1836 1843 2-s2.0-0028239555 10.1001/jama.271.23.1836 (Pubitemid 24169697)
31. Opal S. M., Fisher C. J., Dhainaut J. F. A., Vincent J. L., Brase R., Lowry S. F., Sadoff J. C., Slotman G. J., Levy H., Balk R. A., Shelly M. P., Pribble J. P., LaBrecque J. F., Lookabaugh J., Donovan H., Dubin H., Baughman R., Norman J., DeMaria E., Matzel K., Abraham E., Seneff M., Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Critical Care Medicine 1997 25 7 1115 1124 2-s2.0-0030877935 10.1097/00003246-199707000-00010 (Pubitemid 27310249)
32. Bernard G. R., Statins for acutely hospitalized patients: randomized controlled trials are long overdue. Critical Care 2010 14 2 141 2-s2.0-78149239103 10.1186/cc8950
33. Christensen S., Thomsen R. W., Johansen M. B., Pedersen L., Jensen R., Larsen K. M., Larsson A., Tønnesen E., Sørensen H. T., Preadmission statin use and one-year mortality among patients in intensive care-a cohort study. Critical Care 2010 14 2 R29 2-s2.0-77954312518 10.1186/cc8902
34. Björkhem-Bergman L., Bergman P., Andersson J., Lindh J. D., Statin treatment and mortality in bacterial infections-a systematic review and meta-analysis. PloS one 2010 5 5 e10702 2-s2.0-77956280190 10.1371/journal.pone. 0010702
35. Janda S., Young A., FitzGerald J. M., Etminan M., Swiston J., The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. Journal of Critical Care 2010 25 4 656 e7 2-s2.0-77957690690 10.1016/j.jcrc.2010.02.013
36. Tseng M. Y., Hutchinson P. J., Czosnyka M., Richards H., Pickard J. D., Kirkpatrick P. J., Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 2007 38 5 1545 1550 2-s2.0-34247622293 10.1161/STROKEAHA.106.475905 (Pubitemid 46684172)
37. Abraham E., Reinhart K., Opal S., Demeyer I., Doig C., López Rodriguez A., Beale R., Svoboda P., Laterre P. F., Simon S., Light B., Spapen H., Stone J., Seibert A., Peckelsen C., De Deyne C., Postier R., Pettilä V., Sprung C. L., Artigas A., Percell S. R., Shu V., Zwingelstein C., Tobias J., Poole L., Stolzenbach J. C., Creasey A. A., Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Journal of the American Medical Association 2003 290 2 238 247 2-s2.0-0038690407 10.1001/jama.290.2.238 (Pubitemid 37430063)
38. Warren B. L., Eid A., Singer P., Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Journal of the American Medical Association 2001 286 15 1869 1878 10.1001/jama.286.15.1869 (Pubitemid 33010239)
39. Bernard G. R., Vincent J. L., Laterre P. F., LaRosa S. P., Dhainaut J. F., Lopez-Rodriguez A., Steingrub J. S., Garber G. E., Helterbrand J. D., Ely E. W., Fisher C. J., Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 2001 344 10 699 709 2-s2.0-0035826096 10.1056/NEJM200103083441001 (Pubitemid 32204987)
40. Ranieri V. M., Thompson T., Barie P., Drotrecogin alfa (activated) in adults with septic shock. New England Journal of Medicine 2012 366 22 2055 2064 10.1056/NEJMoa1202290
41. Nadel S., Goldstein B., Williams M. D., Dalton H., Peters M., Macias W. L., Abd-Allah S. A., Levy H., Angle R., Wang D., Sundin D. P., Giroir B., Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. The Lancet 2007 369 9564 836 843 2-s2.0-33847687731 10.1016/S0140-6736(07)60411-5 (Pubitemid 46365900)
42. Yamakawa K., Fujimi S., Mohri T., Matsuda H., Nakamori Y., Hirose T., Tasaki O., Ogura H., Kuwagata Y., Hamasaki T., Shimazu T., Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Critical Care 2011 15 3 R123 2-s2.0-79955786719 10.1186/cc10228
43. Lin S. M., Wang Y. M., Lin H. C., Lee K. Y., Huang C. D., Liu C. Y., Wang C. H., Kuo H. P., Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Critical Care Medicine 2008 36 3 683 689 2-s2.0-44449148952 10.1097/CCM.0B013E31816537D8
44. Venet F., Gebeile R., Bancel J., Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. International Immunopharmacology 2011 11 12 2086 2090 10.1016/j.intimp.2011.08.024
45. Kreymann K. G., De Heer G., Nierhaus A., Kluge S., Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Critical Care Medicine 2007 35 12 2677 2685 2-s2.0-36448938357 10.1097/01.CCM.0000295263. 12774.97 (Pubitemid 350175761)
46. Laupland K. B., Kirkpatrick A. W., Delaney A., Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Critical Care Medicine 2007 35 12 2686 2692 2-s2.0-36448996190 10.1097/01.CCM.0000295312.13466.1C (Pubitemid 350175762)
47. Turgeon A. F., Hutton B., Fergusson D. A., McIntyre L., Tinmouth A. A., Cameron D. W., Hébert P. C., Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Annals of Internal Medicine 2007 146 3 193 203 2-s2.0-33847009520 (Pubitemid 351650633)
48. El-Nawawy A., El-Kinany H., El-Sayed M. H., Boshra N., Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. Journal of Tropical Pediatrics 2005 51 5 271 278 2-s2.0-27144491108 10.1093/tropej/fmi011 (Pubitemid 41508688)
49. Brocklehurst P., Farrell B., King A., Treatment of neonatal sepsis with intravenous immune globulin. New England Journal of Medicine 2011 365 13 1201 1211 10.1056/NEJMoa1100441
50. Bo L., Wang F., Zhu J., Li J., Deng X., Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Critical Care 2011 15 1 R58 2-s2.0-79751531129 10.1186/cc10031
51. Schefold J. C., Immunostimulation using granulocyte- and granulocyte-macrophage colony stimulating factor in patients with severe sepsis and septic shock. Critical Care 2011 15 2 136 10.1186/cc10092
52. Meisel C., Schefold J. C., Pschowski R., Baumann T., Hetzger K., Gregor J., Weber-Carstens S., Hasper D., Keh D., Zuckermann H., Reinke P., Volk H. D., Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. American Journal of Respiratory and Critical Care Medicine 2009 180 7 640 648 2-s2.0-70349469854 10.1164/rccm.200903-0363OC
53. Docke W. D., Randow F., Syrbe U., Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nature Medicine 1997 3 6 678 681 10.1038/nm0697-678 (Pubitemid 27264980)
54. Holmes C. L., Russell J. A., Walley K. R., Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003 124 3 1103 1115 2-s2.0-0141800036 10.1378/chest.124.3.1103 (Pubitemid 37123334)
55. Wong H. R., Genetics and genomics in pediatric septic shock. Critical Care Medicine 2012 40 5 1618 1626 10.1097/CCM.0b013e318246b546
56. Beyster M. A., Hardison D., Lubin G., Improving clinical trials by implementing information technology (IT): where will you be in five years? Implementing Information Technology to Improve the Clinical Trial Process, 2005
57. U.S. Department of Health and Human Services, Food and Drug Administration, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products 2004 Silver Spring, Md, USA U.S. Department of Health and Human Services, Food and Drug Administration